Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine
| Autor: | Emmanuel B. Walter, Rebecca C. Brady, Irene Graham, Maryanne V. Skeljo, Gunter Hartel, James D Campbell, Jillian Bennet, Cornelia L. Dekker, Kathryn M. Edwards, Thomas R. Cate, Dora Y. Ho, Neil Formica, H. Keipp Talbot, John J. Treanor, Wendy A. Keitel, Patricia L. Winokur |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Influenza vaccine medicine.disease_cause Vial Article Young Adult Influenza A Virus H1N1 Subtype Double-Blind Method Influenza Human Influenza A virus Humans Medicine Adverse effect General Veterinary General Immunology and Microbiology business.industry Influenza A Virus H3N2 Subtype Thimerosal Immunogenicity Public Health Environmental and Occupational Health virus diseases Middle Aged Virology Vaccination Influenza B virus Titer Infectious Diseases Vaccines Inactivated Influenza Vaccines Immunology Molecular Medicine Female business |
| Zdroj: | Vaccine. 26:4057-4061 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2008.05.024 |
| Popis: | To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18-64) were randomized to receive either a single dose of TIV from multi-dose vials with thimerosal, TIV from pre-filled syringes without thimerosal, or placebo. Of the TIV recipients, 97.8% achieved a post-vaccination titer > or =40 against H1N1, 99.9% against H3N2 component, and 94.2% against influenza B. Few local or systemic adverse events were noted after vaccination with either TIV presentation. TIV was well tolerated and immunogenic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect